By Chris Wack


Adaptimmune Therapeutics PLC shares were up 24% to $6.10 Tuesday after the company said it entered into a strategic collaboration and license agreement with Genentech, a member of Roche Holding AG, to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.

Volume for the stock was 28 million shares at 12:55 p.m. ET, compared with a 65-day average volume of 832,000 shares. The stock hit its 52-week low of $3.37 on July 27.

The company said the collaboration has two components, development of allogeneic T-cell therapies for up to five shared cancer targets, and development of personalized allogeneic T-cell therapies.

For each component, Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell derived allogeneic platform to produce T-cells. Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.

Adaptimmune will receive an upfront payment of $150 million and additional payments of $150 million over five years, unless the agreement is terminated earlier. Adaptimmune may also be eligible to receive research, development, regulatory and commercial milestones payments potentially exceeding $3 billion.

Adaptimmune will also receive tiered royalties on net sales in the mid-single to low-double digits.

Adaptimmune has the right to opt in to a 50/50 U.S. profit/cost share on "off-the-shelf" products. If Adaptimmune elects to opt in, it will be eligible to share 50% of profits and losses from U.S. sales on such products and is eligible to receive ex-U.S. regulatory and sales-based milestone payments, as well as royalties on ex-U.S. net sales.

SVB Leerink raised its price target for Adaptimmune to $6 from $5 a share, while maintaining its market perform recommendation.


Write to Chris Wack at


(END) Dow Jones Newswires

September 07, 2021 13:17 ET (17:17 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Roche (QX) Charts.
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Roche (QX) Charts.